Latest News - Psoriasis

Monday, October 16, 2017 | PracticalDermatology.com, Research and Publications

Ortho Dermatologics: Long-term Efficacy Data for Siliq

Siliq™ (brodalumab) injection provided sustained high levels of skin clearance (PASI 100) over more than two years in patients with moderate-to-severe psoriasis, according to data presented at t…

Read the full story

Friday, October 13, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Product Launches and Updates

FDA Approves Stelara for Treatment of Adolescents with Moderate To Severe Plaque Psoriasis

The FDA approved an expanded indication for Janssen Biotech, Inc.'s Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with moderate to severe plaque psoriasis who a…

Read the full story

Tuesday, October 03, 2017 | PracticalDermatology.com, Psoriasis

Penn Derm Awarded $8.6M to Study Home Versus In-Office Phototherapy Treatment for Psoriasis

A research team at the University of Pennsylvania will receive $8.6 million to study the effectiveness of home-based phototherapy treatments for psoriasis compared to treatments that require a visit t…

Read the full story

Wednesday, September 20, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Research and Publications

Two-Year Data: TREMFYA™ (guselkumab) Achieves Consistent Rates of Skin Clearance in Moderate to Severe Plaque Psoriasis

New longer-term data from the open-label extension of the VOYAGE 1 trial demonstrate consistent rates of skin clearance with TREMFYA™ treatment through week 100 among patients with moderate…

Read the full story

Wednesday, September 13, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Novartis

Five-Year Data Show Sustained Efficacy, Safety for Cosentyx

Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase …

Read the full story

Wednesday, September 13, 2017 | PracticalDermatology.com, Research and Publications, Psoriasis

IPC, Others Call for Creation of Worldwide Psoriasis Database

A new report calls for the creation of a web-based Global Psoriasis Atlas (GPA) database that will document the prevalence and incidence of psoriasis worldwide. The report, entitled "Global St…

Read the full story

Monday, September 11, 2017 | Phase 3/4 Trials, PracticalDermatology.com, PracticalDermatology.com, Research and Publications

Lilly to Present New Data for Olumiant® and Taltz® at EADV

Eli Lilly and Company will present Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the treatment of moderate-to-severe atopic dermatitis (Lilly and Incyte Corporation …

Read the full story

Thursday, September 07, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Research and Publications

Dermira Presents New Data on Late-Stage Programs at European Dermatology Congress

Dermira, Inc. will present data from its glycopyrronium tosylate (formerly DRM04) and Cimzia (certolizumab pegol) Phase 3 clinical programs in poster sessions at the 26th European Academy of Dermatolo…

Read the full story

Thursday, August 31, 2017 | FDA Approval/Clearance, Healthcare Trends, Phase 3/4 Trials, PracticalDermatology.com, PracticalDermatology.com, Product Launches and Updates, Research and Publications

GBI Research: Global Dermatology Pipeline Will See Shift Toward Increased Use of Biologics

The global dermatology pipeline, which currently comprises 850 products with a disclosed stage of development, is primarily made up of drugs at an early stage of development, with the late stages of t…

Read the full story

Tuesday, August 29, 2017 | Corporate Lawsuits, FDA Approval/Clearance, PracticalDermatology.com, AbbVie, Boehringer Ingelheim, Psoriasis

FDA Greenlights Humira Biosim Cyltezo for Multiple Inflammatory Diseases

The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals, Inc.’s Cyltezo™, a biosimilar to Humira®, in a pre-filled syringe for the treatment of multip…

Read the full story

Tuesday, August 29, 2017 | PracticalDermatology.com, Research and Publications, Psoriasis

Psoriasis Severity Linked to Increased Risk of Death

The more surface area of the body covered by psoriasis, the greater the risk of death, according to a new analysis by researchers at the Perelman School of Medicine at the University of Pennsylva…

Read the full story

Friday, August 25, 2017 | PracticalDermatology.com, National Psoriasis Foundation

National Psoriasis Foundation Honors Research Award Recipients at Biennial Research Symposium

The National Psoriasis Foundation (NPF) recognized two distinguished research professionals for their unique impact on psoriatic disease research during the 2017 NPF Research Symposium. The NPF Med…

Read the full story

Friday, August 04, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Pfizer

FDA Advisory Arm Backs XELJANZ for PsA

The United States Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommends the approval of Pfizer's XELJANZ® (tofacitinib) for the treatment of adults with active pso…

Read the full story

Thursday, July 27, 2017 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, Product Launches and Updates, Atopic Derm, Atopic Dermatitis , Eczema, Psoriasis, Valeant NJ

Valeant’s Newly Minted Ortho Dermatologic Unit Makes Big Splash at Summer AAD

It’s go big or go home for the newly re-branded Valeant Ortho Dermatologic division. At the 2017 American Academy of Dermatology in New York City, the company will officially launch …

Read the full story

Thursday, July 27, 2017 | PracticalDermatology.com, Product Launches and Updates, AbbVie, Boehringer Ingelheim

Boehringer Ingelheim Begins Interchangeability Study Between Adalimumab Biosim and Humira

The first patient has been enrolled into the VOLTAIRE-X interchangeability study, which seeks to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 4…

Read the full story
Load More